Article
Polymorphisms and pharmacogenomics for the toxicity of methotrexate monotherapy in patients with rheumatoid arthritis: A systematic review and meta-analysis.
Medicine - 1 Mar 2017
Qiu Qi, Huang Jing, Lin Yang, Shu Xiaoming, Fan Huizheng, Tu Zhihua, Zhou Youwen, Xiao Cheng
Abstract excerpt
BACKGROUND: Methotrexate (MTX) is widely used and considered a first-line disease modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA). However, 10% to 30% of patients discontinue therapy within a year of starting the treatment, usually because of undesirable side effects. Many of the relevant genes have been investigated to estimate the association between gene polymorphisms and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
